Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Zevra Therapeutics (ZVRA) over the last 10 years, with Q3 2025 value amounting to $554000.0.

  • Zevra Therapeutics' Capital Expenditures changed N/A to $554000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $866000.0, marking a year-over-year increase of 110277.78%. This contributed to the annual value of $296000.0 for FY2023, which is 21827.96% up from last year.
  • As of Q3 2025, Zevra Therapeutics' Capital Expenditures stood at $554000.0.
  • Zevra Therapeutics' Capital Expenditures' 5-year high stood at $554000.0 during Q3 2025, with a 5-year trough of $4000.0 in Q1 2021.
  • In the last 4 years, Zevra Therapeutics' Capital Expenditures had a median value of $29000.0 in 2023 and averaged $90466.7.
  • As far as peak fluctuations go, Zevra Therapeutics' Capital Expenditures surged by 202500.0% in 2021, and later crashed by 8051.95% in 2022.
  • Zevra Therapeutics' Capital Expenditures (Quarter) stood at $17000.0 in 2021, then soared by 100.0% to $34000.0 in 2022, then soared by 111.76% to $72000.0 in 2023, then surged by 669.44% to $554000.0 in 2025.
  • Its last three reported values are $554000.0 in Q3 2025, $213000.0 for Q2 2025, and $99000.0 during Q1 2025.